Pembrolizumab, a new immunotherapy drug, shows lasting tumor control and improved overall survival in advanced Merkel cell carcinoma patients. The study reports generally manageable side effects and supports the use of immunotherapy as an effective treatment option for this aggressive form of skin cancer.
New DNA-based nanomachines can selectively target malignant cells, breaking down vital genes and inducing apoptotic death. The design allows for better interaction with folded RNA molecules, but further experiments are needed to improve specificity.
Researchers discovered a novel metabolic pathway in cancer cells that produces an unusual fatty acid, sapienate, allowing them to bypass fatty acid metabolism inhibition. This finding can explain the resistance of certain cancer types to therapy and opens new avenues for targeted treatment.
Researchers at Penn State College of Medicine identified 10 synthetic cannabinoid compounds that effectively inhibited the growth of seven types of human colon cancer cells. These compounds work through alternative mechanisms, not relying on traditional marijuana receptors, and hold promise for developing drugs to treat cancer.
Scientists have discovered how DNA topoisomerase II and CKII enzymes in fission yeast interact to promote cell growth, a mechanism that may be similar in human cancer cells. Inhibiting these enzymes could lead to new cancer treatments.
A new study led by Grant Brown suggests that at times of stress, DNA replication errors are far more frequent than previously appreciated. This could lead to increased mutations in human cells, potentially contributing to cancer and other diseases.
Researchers at the University of Seville have characterized the normal electrical activity in PC-3 prostate cancer cells, showing a low-frequency pattern between 0.1 and 10 Hz. This study aims to explore the relationship between electrical patterns and cell proliferation, with potential applications for medicine delivery.
A new compound based on Iridium, a rare metal, can penetrate into cancerous cells and deliver iridium, killing them when exposed to light. The discovery could lead to effective treatment against resistant cancers with reduced side effects.
Scientists have discovered proteins that regulate mucin production in the body, which could lead to new treatments for diseases such as asthma and colorectal cancer. The study also found a calcium sensor protein that controls the thickness of the mucus layer in the colon.
New research shows cancer cells cause premature ageing in healthy bone marrow cells, leading to faster disease progression. The study identifies NOX2 enzyme as key player in this process, highlighting potential for new treatments.
Researchers engineered a virus that selectively targets and kills cancer cells, surpassing another viral treatment currently in use. The modified adenovirus, dl355, replicates more efficiently in cancer cells than normal cells, resulting in higher cancer cell kill rates.
Scientists have isolated a gene, miR-I35B, linked to both inflammation and gastric cancer. The study suggests that miR-135B plays a role in the development of gastric abnormalities and may help develop diagnostic tools for early detection.
A study published in Life Science Alliance found that the enzyme D-amino acid oxidase (DAO) promotes cellular senescence and aging by producing reactive oxygen species. By inducing DNA double-strand breaks, researchers found increased expression of DAO is dependent on p53, a cancer-suppressing protein.
A study by Salk researchers found that autophagy, a process thought to be a survival mechanism, actually promotes cell death and prevents cancer initiation. This discovery reveals autophagy as a novel tumor-suppressing pathway and challenges the conventional understanding of cancer development.
Researchers have discovered a promising new drug that targets the biological clock of cancer cells, slowing their growth and halting their spread. By disrupting the circadian rhythm of cancer cells, this drug may provide an effective new treatment option for various types of cancer.
Researchers at the University of Pennsylvania School of Medicine have identified a method to fuel macrophages with energy needed to attack and eat cancer cells. By rewiring macrophage metabolism, macrophages can overcome signals that prevent them from attacking tumors, leading to tumor shrinkage and prolonged survival in mice.
Scientists have discovered two methods to mend DNA-protein crosslinks and established how DNA replication triggers these repair processes. The researchers hope their findings can be used to develop more efficient combination treatments for cancer cells.
Researchers at Ural Federal University have synthesized multi-purpose fluorophores that can track the absorption of medications in the body, helping diagnose cancer. The technology has far-reaching implications for pharmaceuticals and environmental analysis, offering a low-cost and sustainable alternative to traditional methods.
A team of scientists has successfully developed a hybrid molecule that uses light therapy to stop tumor growth in mice, with a remarkable 70% success rate. The innovative approach combines photodynamic therapy with targeted drug delivery, allowing for precise elimination of malignant cells and reduced toxicity.
Researchers at the University of Sussex have identified a protein partner that promotes β-catenin's movement into the nucleus of myeloid leukaemia cells, driving cancer development. This finding could lead to the development of targeted therapies to treat acute myeloid leukaemia (AML), with potential benefits for up to 80% of cases.
Researchers studied HeLa cells and found that cancer cells accumulate harmful mutations, but about 13% of cells remain mutation-free. This allows them to survive despite reducing their growth rate and chromosome numbers. The study suggests that high rates of deleterious mutations are necessary for the population to die out.
Researchers have discovered molecular mechanisms that enable the transmission of a deadly facial tumor among Tasmanian devils. The study found that ERBB receptors and STAT3 proteins play a key role in the transmissibility of the disease, which has killed 90% of the wild population.
Researchers created Cas9-CPs and ProCas9s, which simplify genome editing and epigenetic modifications. These variants enable molecular sensing, tissue-specific genome editing, and potential application as a pathogen-sensing system.
Researchers have designed a new Cas9 enzyme, ProCas9, that can be controlled by specific enzymes present in cells or viruses. This allows for more accurate and precise gene editing with added security. The technology has potential applications in treating diseases and improving crop resistance to viral pathogens.
Researchers at Osaka University have identified Semaphorin 7a as a protein involved in treatment resistance in lung cancer cells with common EGFR mutations. High levels of Semaphorin 7a inhibit apoptosis, making it harder for cancerous cells to be eradicated.
Researchers at Emory University have developed a high-throughput screening platform to identify small molecules that can enhance the ability of human immune cells to kill cancer cells. The platform, called HTiP, has identified compounds such as birinapant, which has shown strong evidence for its relevance as an immune enhancer.
Researchers have discovered a new population of immune cells that respond to immunotherapy treatment, as well as a critical molecular factor required for the therapy's success. The study highlights the importance of early-stage T cells and the need for further understanding of how checkpoint blockade therapies work.
Yeast cells produce ethanol as a 'safety valve' when their metabolic operation reaches a critical level. This discovery also explains the Warburg effect in cancer cells, where energy is wasted by producing lactate.
Cells utilize membrane tension to regulate endocytosis and maintain homeostasis. A protein called vinculin senses changes in force and regulates the CLIC/GEEC pathway to control endocytic processes.
Researchers at São Paulo State University synthesized a compound called GA-Hecate that effectively inhibits the replication of hepatitis C virus (HCV) in multiple stages. The compound also displays activity against bacteria, fungi, and cancer cells, and is being tested against Zika and yellow fever viruses.
A specific transcription factor called JunB helps control the activity of effector regulatory T cells, which suppress immune activity. Without JunB regulation, mice develop severe inflammation in their lungs and colons, suggesting JunB prevents autoimmunity in specific organs.
Researchers found that metformin and syrosingopine combination blocks critical energy production step, driving cancer cells to death. The duo targets NAD+ regeneration, preventing lactate export and leading to cell demise.
Scientists have developed a new technique using light to detect signaling molecule secretion from individual cells, allowing for the simultaneous analysis of cell behavior over time. This enables early detection of diseases such as cancer and blood clots, which is critical for improving survival rates.
Researchers at Osaka University have developed an AI-based system that can automatically differentiate between various types of cancer cells using microscopic images. The system achieved higher accuracy than human judgment, making it a potential game-changer in cancer diagnosis and treatment.
Researchers at the Weizmann Institute of Science have created a new method to sequence individual cells from patient blood or bone marrow, capturing specific gene programs active in each cell. This allows for more precise diagnosis and treatment of multiple myeloma by identifying unique genetic blueprints for each patient.
Scientists at DKFZ developed XRNAX to analyze interactions between all RNA classes with cellular proteins. The new method identifies hundreds of previously unknown protein-RNA bindings and sheds light on diseases including cancer, ALS, and viral infections.
Researchers have engineered sensors to monitor multiple signaling pathways driving tumor metastasis, enabling the prediction of a tumor cell's potential to spread. The development of Fluorescence Resonance Energy Transfer (FRET) biosensors has the potential to transform cancer cell biology and inform personalized treatment strategies.
Researchers at WashU Medicine have designed a 'flight data recorder' for developing cells, revealing the paths they take as they progress from one type to another. This tool has potential to boost regenerative medicine by guiding skin cells into new liver cells and may also be applied in cancer research.
A new method for detecting bladder cancer has been developed using atomic force microscopy (AFM), which can accurately identify cancerous cells in urine samples with high sensitivity. The test demonstrates over 90% sensitivity in detecting bladder cancer, compared to 20-80% for current non-invasive diagnostics.
A UCalgary research team analyzed publicly accessible health and genomics data to identify a gene signature that can help determine which cancer patients will benefit from immunotherapy. This discovery has the potential to improve treatment outcomes for these patients.
Researchers from Princeton University developed new light-harnessing systems to probe membraneless organelle formation and its impact on cellular DNA. The discovery sheds light on the role of these organelles in diseases like cancer, Alzheimer's, and ALS.
Researchers developed a new wound dressing that applies gentle electrical pulses using energy from body motions, significantly speeding up healing times in rodent tests.
Researchers at the University of Zurich identified a molecule that plays a key role in graft-versus-host responses, which can be fatal for leukemia patients. Blocking this molecule, GM-CSF, could significantly improve stem-cell transplant outcomes.
A study found that restricting cancer cells' ability to metabolize sugar makes oncolytic viruses work better, multiplying faster and destroying cancer quicker. This approach may improve how potential cancer drugs are investigated in the lab.
Researchers at Max Delbrück Center develop strategy to selectively make cancer cells aggressive, making them vulnerable to anti-inflammatory substance. This approach aims to overcome chemotherapy resistance in certain types of cancer, such as non-small cell lung cancer.
Research unravels mechanism of defective ribosomes causing cellular damage, including DNA mutations and increased cancer protein levels. The discovery provides a solution to Dameshek's Riddle and turns ribosome defects into an attractive target in the fight against cancer.
Scientists visualize immune system's action on tumor development, revealing its impact on cancer cell heterogeneity. The study highlights the potential for optimizing therapeutic combinations and sequences to improve immunotherapy outcomes.
Researchers developed a mathematical model showing that two types of cellular asymmetry govern the shaping of cells into sheets and tubes. Altering one polarity can simulate diverse shapes, with initial cell arrangement and external boundaries influencing outcomes.
Researchers fully described the mechanism of fungal luminescence, utilizing four key enzymes to produce light. They also created an entirely new molecular instrument for biotechnology by engineering a yeast strain that glows in the dark.
Researchers at Walter and Eliza Hall Institute identified a new component of the cell death machinery, protein VDAC2, which plays a crucial role in driving apoptosis in cancer cells. The study reveals that VDAC2 helps Bax drive apoptosis and may fine-tune cancer cells' response to anti-cancer agents.
A lab study funded by Cancer Research UK and Worldwide Cancer Research found that mannose can slow tumour growth and enhance the effects of chemotherapy in mice with multiple types of cancer. The researchers discovered a dosage of mannose that could block enough glucose to slow tumour growth in mice without affecting normal tissues.
Scientists at Lancaster University created a fluorescent biosensor to visualize cilia and cell division simultaneously, enabling the study of their interplay in development, regeneration, and disease. This new tool will help researchers understand how changes in cilia dynamics affect cell division speed and tissue development.
Researchers have discovered a new compound, ancistrolikokine E3, from a Congolese rainforest vine that effectively targets and kills pancreatic cancer cells. The compound inhibits the Akt/mTOR pathway and autophagy pathway, leading to dramatic changes in cell morphology and preventing metastasis formation.
Researchers have identified a compound, ancistrolikokine E3, from the twigs of the Ancistrocladus likoko vine that kills pancreatic cancer cells when nutrients are scarce. The compound inhibits the Akt/mTOR pathway, which is responsible for the aggressive proliferation of these cancer cells.
Ralph DeBerardinis' work has changed the understanding of how tumors reprogram metabolic pathways to maximize energy production and growth. His discoveries have opened new avenues for therapies and imaging techniques, targeting cancer cells' diverse metabolic preferences.
A team of researchers developed new strategies to exploit CRISPR technology to target the mutant form of protein NPM1, which is associated with acute myeloid leukemia. By blocking the export of mutant NPM1 from the nucleus, they were able to inhibit leukemic cell growth and induce differentiation or death in cancerous cells.
New research reveals Gamma Delta T cells possess a two-pronged device to check cell health before killing cancer cells. The immune cells can act independently without relying on authorization from other signals.
A genetic test called ThyroSeq has been shown to reliably distinguish between benign and cancerous thyroid nodules using a small sample of cells. The test correctly identified cancerous nodules as positive 94% of the time and detected benign nodules as negative 82% of the time, preventing unnecessary diagnostic surgeries.
A new analysis of E. coli cell data sheds light on the long-standing question of what triggers cell division, suggesting that both DNA replication and septum formation occur concurrently. This discovery challenges existing models and offers new perspectives on cellular growth and potential applications in understanding cancer.
A team led by Dr. Sjoerd van Wijk is exploring M1-deubiquitinating enzymes and their interactions with death receptors to better comprehend programmed cell death regulation. This research may lead to insights into human diseases, such as cancer development and bacterial invasion.